Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Animal Health’s Advantix demonstrates efficacy in study

Bayer Animal Health’s Advantix demonstrates efficacy in study

6th July 2010

Bayer Animal Health has highlighted data from a new study which illustrates the potential benefits offered by its canine vector-borne disease (CVBD) treatment Advantix.

The therapy was trialled in a landmark international prevention field study, results of which have been published in the journal Veterinary Parasitology, to establish its effectiveness in protecting dogs from diseases spread by ticks and sand flies over two years.

It was found that use of the Bayer treatment was associated with a 90 per cent reduction in CVBD cases, including a 94.6 per cent drop in ehrlichiosis and a complete elimination of new cases of leishmaniosis.

Sarah Weston of Bayer Animal Health’s global veterinary services division, said the importance of treating such conditions has been heightened by an increase in international travel among pets.

She added: “This study demonstrates that using Advantix is an effective way to protect pets from bites of ticks and sand flies, reducing the risk of CVBD transmission.”

This comes after, Bayer Animal Health launched a series of online videos earlier this year which were designed to raise awareness among pet owners of the dangers of CVBD and other parasite-related health conditions.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.